Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients
- PMID: 8297213
- DOI: 10.1001/archpsyc.1994.03950020063007
Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients
Abstract
Psychiatric researchers need specific animal models to better understand the neurobiology of schizophrenia. Prepulse inhibition (PPI), the reduction in startle produced by a prepulse stimulus, is diminished in schizophrenic patients. Theoretically, deficient PPI in schizophrenic patients reflects a loss of sensorimotor gating that may lead to sensory flooding and cognitive fragmentation. In rats, PPI is disrupted by systemic administration of dopamine agonists or by manipulations of neural circuitry linking the limbic cortex, striatum, pallidum, and pontine reticular formation. This loss of PPI in rats may be a useful model for studying the neurobiology of impaired sensorimotor gating in schizophrenic patients. We assessed the face, predictive, and construct validity of this animal model. Face validity was supported: stimulus manipulations produced parallel changes in PPI in humans and rats, and the dopamine agonist apomorphine disrupted PPI in rats, mimicking PPI deficits in schizophrenics. Predictive validity was supported: the ability of antipsychotics to restore PPI in apomorphine-treated rats correlated with clinical antipsychotic potency (rs = .991) and D2-receptor affinity (rs = .893). Antipsychotics that restore PPI in apomorphine-treated rats include "typical" antipsychotics and the "atypical" antipsychotic clozapine. Construct validity was supported: PPI was disrupted in rats when dopamine was infused into the nucleus accumbens; this effect was blocked by haloperidol. The loss of PPI in dopamine-activated rats may be a valid animal model of sensorimotor gating deficits in schizophrenic patients. This model may help us understand the neurobiology of cognitive deficits in schizophrenic patients.
Similar articles
-
Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia.Schizophr Bull. 1998;24(2):285-301. doi: 10.1093/oxfordjournals.schbul.a033326. Schizophr Bull. 1998. PMID: 9613626 Review.
-
Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review.Psychopharmacology (Berl). 2001 Jul;156(2-3):117-54. doi: 10.1007/s002130100811. Psychopharmacology (Berl). 2001. PMID: 11549216 Review.
-
Clozapine and haloperidol in an animal model of sensorimotor gating deficits in schizophrenia.Pharmacol Biochem Behav. 1993 Mar;44(3):741-4. doi: 10.1016/0091-3057(93)90193-w. Pharmacol Biochem Behav. 1993. PMID: 8451276
-
Towards a cross-species pharmacology of sensorimotor gating: effects of amantadine, bromocriptine, pergolide and ropinirole on prepulse inhibition of acoustic startle in rats.Behav Pharmacol. 1998 Sep;9(5-6):389-96. doi: 10.1097/00008877-199809000-00002. Behav Pharmacol. 1998. PMID: 9832924
-
Increased sensitivity to the sensorimotor gating-disruptive effects of apomorphine after lesions of medial prefrontal cortex or ventral hippocampus in adult rats.Psychopharmacology (Berl). 1995 Nov;122(1):27-34. doi: 10.1007/BF02246438. Psychopharmacology (Berl). 1995. PMID: 8711061
Cited by
-
Impaired sensorimotor gating in unmedicated adults with obsessive-compulsive disorder.Neuropsychopharmacology. 2012 Apr;37(5):1216-23. doi: 10.1038/npp.2011.308. Epub 2012 Jan 4. Neuropsychopharmacology. 2012. PMID: 22218093 Free PMC article.
-
Promise and pitfalls of animal models of schizophrenia.Curr Psychiatry Rep. 2010 Aug;12(4):327-34. doi: 10.1007/s11920-010-0122-x. Curr Psychiatry Rep. 2010. PMID: 20544314 Free PMC article. Review.
-
Reversal of isolation-rearing-induced PPI deficits by an alpha7 nicotinic receptor agonist.Psychopharmacology (Berl). 2005 Oct;182(2):214-9. doi: 10.1007/s00213-005-0069-5. Epub 2005 Oct 19. Psychopharmacology (Berl). 2005. PMID: 16001118
-
Effects of NRA0045, a novel potent antagonist at dopamine D4, 5-HT2A, and alpha1 adrenaline receptors, and NRA0160, a selective D4 receptor antagonist, on phencyclidine-induced behavior and glutamate release in rats.Psychopharmacology (Berl). 2003 Sep;169(3-4):247-56. doi: 10.1007/s00213-003-1517-8. Epub 2003 Jul 31. Psychopharmacology (Berl). 2003. PMID: 12898123
-
Pharmacological characterization and CNS effects of a novel highly selective alpha2C-adrenoceptor antagonist JP-1302.Br J Pharmacol. 2007 Feb;150(4):391-402. doi: 10.1038/sj.bjp.0707005. Epub 2007 Jan 15. Br J Pharmacol. 2007. PMID: 17220913 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical